Gilead Nears $2 Billion Acquisition of Ouro Medicines
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 23 2026
0mins
Source: seekingalpha
- Acquisition Negotiations: Gilead Sciences (GILD) is nearing a potential acquisition of autoimmune-focused biotech Ouro Medicines for up to $2 billion, indicating its strategic intent to expand in the biopharmaceutical sector.
- Cash Payment Structure: Under the deal terms, Gilead is expected to pay Ouro's investors approximately $1.5 billion upfront in cash, with an additional $500 million contingent on achieving specific clinical trial milestones, thereby mitigating acquisition risks.
- Clinical Trial Milestones: The success of this transaction will hinge on Ouro's performance in clinical trials, as meeting these milestones could yield long-term benefits for Gilead, further solidifying its market position in the autoimmune disease sector.
- Market Reaction Anticipation: As acquisition discussions advance, the market is responding positively to Gilead's stock, with an announcement expected in the coming days, which could enhance investor confidence in the company's future growth prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GILD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GILD
Wall Street analysts forecast GILD stock price to rise
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 127.570
Low
105.00
Averages
137.88
High
154.00
Current: 127.570
Low
105.00
Averages
137.88
High
154.00
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Livdelzi/Lyvdelzi, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, and others. It also sells and distributes authorized generic versions of Epclusa and Harvoni in the United States through its subsidiary, Asegua Therapeutics LLC. It has control on anitocabtagene autoleucel (anito cel), an investigational BCMA-directed CAR T cell therapy for multiple myeloma. The Company also owns an antibody-drug conjugates (ADCs) platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gilead Sciences Reports Positive Phase 3 IDEAL Trial Results for Livdelzi
- Phase 3 Trial Results: Gilead Sciences reported that a significantly higher proportion of patients with primary biliary cholangitis achieved normalization of ALP levels with Livdelzi compared to the placebo group in the Phase 3 IDEAL trial, indicating the drug's potential in improving patient outcomes.
- Patient Recruitment: The trial enrolled 96 adults aged 18 to 75 years, all with ALP levels above the normal range who had not achieved normalization despite treatment with ursodeoxycholic acid (UDCA), highlighting Livdelzi's effectiveness in difficult-to-treat cases.
- Future Plans: Gilead plans to present the full IDEAL trial data at an upcoming medical congress and discuss the results with global regulatory authorities, demonstrating the company's confidence in Livdelzi's market potential.
- Market Performance: Gilead's stock has fluctuated between $104.46 and $157.29 over the past year, closing at $127.57 in the latest trading session, reflecting market interest and anticipation regarding its research advancements.
See More
Livdelzi Shows Positive Phase 3 Results in PBC Patients
- Clinical Trial Results: Gilead Sciences announced that the IDEAL study demonstrated that after 52 weeks of treatment, significantly more patients achieved normalization of alkaline phosphatase (ALP), indicating Livdelzi's efficacy in treating primary biliary cholangitis (PBC).
- Safety Profile: The safety profile of Livdelzi observed in the IDEAL study was consistent with previous studies, with no new safety concerns identified, showcasing its good tolerability in clinical applications.
- Achievable Treatment Goals: The findings support ALP normalization as an achievable treatment goal for PBC patients, particularly those with ALP levels between the upper limit of normal and 1.67 times the upper limit, which has significant clinical implications.
- Future Prospects: Gilead plans to present full data at an upcoming medical congress and engage with global regulatory authorities to discuss these results, further advancing Livdelzi's clinical application and market access.
See More
WHO Approves Evaluation of Regeneron's Antibody for Ebola Treatment
- Antibody Evaluation Approval: The World Health Organization has approved the evaluation of Regeneron Pharmaceuticals' antibody maftivimab as a potential treatment for the current Ebola outbreak, reflecting a proactive stance in combating the epidemic.
- Targeting Specific Virus: Maftivimab is one of the antibodies in the FDA-approved Inmazeb, primarily used for Orthoebolavirus zairen, with WHO recommending its prioritization for Bundibugyo ebolavirus to address the outbreaks in the Democratic Republic of the Congo and Uganda.
- Alternative Treatment Options: WHO also suggests evaluating Gilead Sciences' antiviral remdesivir and its experimental drug obeldesivir for post-exposure prophylaxis, aiming to enhance treatment options and response capabilities against the outbreak.
- Vaccine Usage Restrictions: Merck's Ervebo is the only licensed Ebola vaccine; however, WHO emphasizes that it should only be used in carefully designed research settings to assess its effectiveness against Bundibugyo ebolavirus, ensuring safety and efficacy.
See More
New Findings on Livdelzi in PBC Treatment
- Significant ALP Normalization: In the ASSURE study, 83% of participants achieved ALP normalization at 12 months, and 74% maintained this at 24 months, demonstrating Livdelzi's long-term efficacy in treating PBC patients, potentially enhancing their quality of life.
- Improvement in Liver Stiffness: An exploratory analysis showed that 85% of participants who achieved biochemical response at 12 months maintained or improved liver stiffness over three years, indicating that Livdelzi not only lowers ALP but also enhances liver health, boosting treatment confidence.
- Good Safety Profile: Livdelzi showed no treatment discontinuations due to adverse events over two years of follow-up, with no new safety signals observed, indicating its good tolerability in high-risk PBC patients and supporting broader application.
- Clear Treatment Goals: ALP normalization is recognized as a key treatment goal in PBC, and the findings from Livdelzi's studies provide strong support for its use in PBC patients, potentially driving its wider clinical adoption.
See More
Gilead Acquires Tubulis for $3.15B to Enhance Oncology Portfolio
- Acquisition Scale: Gilead Sciences completed the acquisition of Tubulis GmbH for $3.15 billion in upfront payments, with potential milestone payments of up to $1.85 billion, significantly enhancing its oncology portfolio through this strategic move.
- Innovation Center Establishment: Following the acquisition, the Tubulis team will remain in Munich to establish 'The Tubulis ADC Innovation Center,' focusing on research, manufacturing, and clinical development of antibody-drug conjugates, thereby enhancing Gilead's R&D capabilities in cancer treatment.
- Clinical Asset Integration: Tubulis' lead candidate TUB-040 is currently being evaluated for platinum-resistant ovarian and non-small cell lung cancers, and by integrating these clinical assets, Gilead aims to address significant treatment gaps for patients with challenging solid tumors.
- Market Leadership: This acquisition not only solidifies Gilead's leadership position in oncology innovation but also drives the advancement of transformative cancer treatments by combining existing infrastructure with Tubulis' innovative platform, addressing unmet medical needs.
See More
U.S. Stocks Rise as Hopes for Iran Peace Deal Increase
- Strong U.S. Market Performance: The S&P 500 rose by 0.4%, the Dow Jones increased by 0.6%, and the Nasdaq gained 0.2%, marking the longest weekly gain streak since 2023, indicating increased investor confidence in risk assets amid hopes for a U.S.-Iran peace deal.
- Active ETF Market: The SPDR S&P 500 ETF and Invesco QQQ Trust both rose by 0.4%, while the Dow Jones Industrial Average ETF increased by 0.7%, reflecting optimistic sentiment towards major indices, particularly ahead of the upcoming three-day weekend.
- Oil Prices Edge Up: International Brent crude futures added 0.9% to close at $103.54 per barrel, while West Texas Intermediate crude rose about 0.3%, reflecting market hopes for a resolution to the Iran conflict, although still below earlier peaks this week.
- New Fed Chair Sworn In: Kevin Warsh was officially sworn in as the 17th Chair of the Federal Reserve, with market expectations regarding his policy direction likely to influence future monetary policy and economic trends, especially in the context of the current economic recovery.
See More
Gilead Sciences Reports Positive Phase 3 IDEAL Trial Results for Livdelzi
- Phase 3 Trial Results: Gilead Sciences reported that a significantly higher proportion of patients with primary biliary cholangitis achieved normalization of ALP levels with Livdelzi compared to the placebo group in the Phase 3 IDEAL trial, indicating the drug's potential in improving patient outcomes.
- Patient Recruitment: The trial enrolled 96 adults aged 18 to 75 years, all with ALP levels above the normal range who had not achieved normalization despite treatment with ursodeoxycholic acid (UDCA), highlighting Livdelzi's effectiveness in difficult-to-treat cases.
- Future Plans: Gilead plans to present the full IDEAL trial data at an upcoming medical congress and discuss the results with global regulatory authorities, demonstrating the company's confidence in Livdelzi's market potential.
- Market Performance: Gilead's stock has fluctuated between $104.46 and $157.29 over the past year, closing at $127.57 in the latest trading session, reflecting market interest and anticipation regarding its research advancements.
See More
Livdelzi Shows Positive Phase 3 Results in PBC Patients
- Clinical Trial Results: Gilead Sciences announced that the IDEAL study demonstrated that after 52 weeks of treatment, significantly more patients achieved normalization of alkaline phosphatase (ALP), indicating Livdelzi's efficacy in treating primary biliary cholangitis (PBC).
- Safety Profile: The safety profile of Livdelzi observed in the IDEAL study was consistent with previous studies, with no new safety concerns identified, showcasing its good tolerability in clinical applications.
- Achievable Treatment Goals: The findings support ALP normalization as an achievable treatment goal for PBC patients, particularly those with ALP levels between the upper limit of normal and 1.67 times the upper limit, which has significant clinical implications.
- Future Prospects: Gilead plans to present full data at an upcoming medical congress and engage with global regulatory authorities to discuss these results, further advancing Livdelzi's clinical application and market access.
See More
WHO Approves Evaluation of Regeneron's Antibody for Ebola Treatment
- Antibody Evaluation Approval: The World Health Organization has approved the evaluation of Regeneron Pharmaceuticals' antibody maftivimab as a potential treatment for the current Ebola outbreak, reflecting a proactive stance in combating the epidemic.
- Targeting Specific Virus: Maftivimab is one of the antibodies in the FDA-approved Inmazeb, primarily used for Orthoebolavirus zairen, with WHO recommending its prioritization for Bundibugyo ebolavirus to address the outbreaks in the Democratic Republic of the Congo and Uganda.
- Alternative Treatment Options: WHO also suggests evaluating Gilead Sciences' antiviral remdesivir and its experimental drug obeldesivir for post-exposure prophylaxis, aiming to enhance treatment options and response capabilities against the outbreak.
- Vaccine Usage Restrictions: Merck's Ervebo is the only licensed Ebola vaccine; however, WHO emphasizes that it should only be used in carefully designed research settings to assess its effectiveness against Bundibugyo ebolavirus, ensuring safety and efficacy.
See More
New Findings on Livdelzi in PBC Treatment
- Significant ALP Normalization: In the ASSURE study, 83% of participants achieved ALP normalization at 12 months, and 74% maintained this at 24 months, demonstrating Livdelzi's long-term efficacy in treating PBC patients, potentially enhancing their quality of life.
- Improvement in Liver Stiffness: An exploratory analysis showed that 85% of participants who achieved biochemical response at 12 months maintained or improved liver stiffness over three years, indicating that Livdelzi not only lowers ALP but also enhances liver health, boosting treatment confidence.
- Good Safety Profile: Livdelzi showed no treatment discontinuations due to adverse events over two years of follow-up, with no new safety signals observed, indicating its good tolerability in high-risk PBC patients and supporting broader application.
- Clear Treatment Goals: ALP normalization is recognized as a key treatment goal in PBC, and the findings from Livdelzi's studies provide strong support for its use in PBC patients, potentially driving its wider clinical adoption.
See More
Gilead Acquires Tubulis for $3.15B to Enhance Oncology Portfolio
- Acquisition Scale: Gilead Sciences completed the acquisition of Tubulis GmbH for $3.15 billion in upfront payments, with potential milestone payments of up to $1.85 billion, significantly enhancing its oncology portfolio through this strategic move.
- Innovation Center Establishment: Following the acquisition, the Tubulis team will remain in Munich to establish 'The Tubulis ADC Innovation Center,' focusing on research, manufacturing, and clinical development of antibody-drug conjugates, thereby enhancing Gilead's R&D capabilities in cancer treatment.
- Clinical Asset Integration: Tubulis' lead candidate TUB-040 is currently being evaluated for platinum-resistant ovarian and non-small cell lung cancers, and by integrating these clinical assets, Gilead aims to address significant treatment gaps for patients with challenging solid tumors.
- Market Leadership: This acquisition not only solidifies Gilead's leadership position in oncology innovation but also drives the advancement of transformative cancer treatments by combining existing infrastructure with Tubulis' innovative platform, addressing unmet medical needs.
See More
U.S. Stocks Rise as Hopes for Iran Peace Deal Increase
- Strong U.S. Market Performance: The S&P 500 rose by 0.4%, the Dow Jones increased by 0.6%, and the Nasdaq gained 0.2%, marking the longest weekly gain streak since 2023, indicating increased investor confidence in risk assets amid hopes for a U.S.-Iran peace deal.
- Active ETF Market: The SPDR S&P 500 ETF and Invesco QQQ Trust both rose by 0.4%, while the Dow Jones Industrial Average ETF increased by 0.7%, reflecting optimistic sentiment towards major indices, particularly ahead of the upcoming three-day weekend.
- Oil Prices Edge Up: International Brent crude futures added 0.9% to close at $103.54 per barrel, while West Texas Intermediate crude rose about 0.3%, reflecting market hopes for a resolution to the Iran conflict, although still below earlier peaks this week.
- New Fed Chair Sworn In: Kevin Warsh was officially sworn in as the 17th Chair of the Federal Reserve, with market expectations regarding his policy direction likely to influence future monetary policy and economic trends, especially in the context of the current economic recovery.
See More
